Dr. Mehmet Oz

And for that reason, we now have a bunch of contracts with pharmaceutical companies where they agree voluntarily

to reduce their prices so they're the most favored nation pricing here in America.

It's fair.

It works.

It turns out that these companies have maintained their valuations.

They haven't been hurt by these deals, even though they've taken significant financial haircuts.

The president wants Congress to codify what we already believe works.

We don't want to go any further.

We don't want to cause any more problems for any pharmaceutical companies, for any parts of these negotiations.

We just want to

grandfather in people who have been there and make sure that going forward in future administrations, the drug companies stay committed to this deal structure and that the U.S.

government doesn't overreach its needs and start to do crazy things like cap prices in the pharma space that actually would hurt their innovation.

So that's the big first step, number one, most favored nation, acronym MFN, you'll be hearing that a lot.

Second big area, how do you make insurance companies accountable?

Well, first off, the money that they're getting, it's

This is a good example for the Affordable Care Act, as the president calls it, the Unaffordable Care Act, is a problem because they just take the money, their valuations go up.

The money actually, eventually, some of it gets down to the people, but premiums still keep rising.

So the president said, from now on, we want the money going to the people.

We want to make sure that as much as possible, we drive down prices in the insurance space fairly.

And there's a way of doing that called cost sharing reduction.